Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes

Therapy

Volumn 3, Issue 1, 2006, Pages 119-123

  Larijani, Bagher ^a   Afshari, Mojgan ^a   Astanehi Ashgari, Fatemeh ^b   Mojtahedi, Alireza ^a   Rezaie, Ali ^c   Hosseinnezhad, Arash ^a   Heshman, Ramin ^a   Mohammadirad, Azadeh ^b   Abdollahi, Mohammad ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF CALGARY   (Canada)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood; Carvedilol; Fasting blood sugar; Hemoglobin A1c; Lipid peroxidation; Saliva; Total antioxidant power; Type II diabetes

Indexed keywords

CARVEDILOL; GLUCOSE; HEMOGLOBIN A1C; LIPID; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANALYTICAL PARAMETERS; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; SHORT COURSE THERAPY;

EID: 33646188313     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.1.119     Document Type: Article

References (39)

1. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr. Atheroscler. 3, 383-391 (2001).
2. Giugliano D, Cerielio A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 19, 257-267 (1996).
3. Egan BM, Greene EL, Goodfriend TL. Insulin resistance and cardiovascular disease. Am. J. Hypertens. 14(Suppl.), 116S-125S (2001).
4. Ginsberg HN. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453-458 (2000).
5. Opara EC. Role of oxidative stress in the etiology of type 2 diabetes and the effect of antioxidant supplementation on glycemic control. J. Investig. Med. 52(1), 19-23 (2004).
6. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur. J. Heart Fall. 5 (6), 803-809 (2003).
7. Stroe AF, Gheorghiade M.Carvedilol. β-blockade and beyond. Rev. Cardiovasc. Med. 5(Suppl. 1), S18-S27 (2004).
8. Metra M, Nodari S, Parrinello, G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-termb-blockade inpatients with chronic heart failure: clinical correlates and prognostic significance. Am. Heart J. 145(2), 292-299 (2003).
9. Haas SJ, Vos T, Gilbert RE, Krum H. Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am. Heart J. 146, 848-853 (2003).
10. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am. J. Hypertens. 11, 1258-1265 (1998).
11. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med. 126, 955-959 (1997).
12. Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity: the carvedilol metoprolol study. J. Hypertens. 14, 489-494 (1996).
13. Book WM. Carvedilol. A nonselective β-blocking agent with antioxidant properties. Congest. Heart Fall. 8, 173-177, 190 (2002).
14. Yue TL, Cheng HY, Lysko PG et al. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol.
15. Yue TL, McKenna PJ, Gu JL et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 22, 922-928 (1993).
16. Benzi IF, Strain S. Ferric reducing antioxidant assay. Methods Enzymol. 292, 15-27 (1999).
17. Satho K. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin. Chem. Acta. 90, 37-43 (1978).
18. Schifreen RS, Hickingbotham JM. Bowers GN Jr. Accuracy, precision, and stability in measurement of hemoglobin A1c by 'high-performance' cation-exchange chromatography. Clin. Chem. 26(3), 466-472 (1980).
19. Oliveira PJ, Esteves T, Rolo AP et al. Carvedilol, relation between antioxidant activity and inhibition of the mitochondrial permeability transition. Rev. Port. Cardiol. 22(1), 55-62 (2003).
20. Oliveira PJ, Rolo AP, Palmeira CM, Moreno AJ. Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury. Cardiovasc. Toxicol. 1(3), 205-213 (2001).
21. Abreu RM, Santos DJ, Moreno AJ. Effects of carvedilol and its analog BM-910228 on mitochandriol function and oxidative stress. J. Pharmacol. Exp. Ther. 295(3), 1022-1030 (2000).
22. Singh D, Chander V, Chopra K. Carvedilol, an antihypertensive drug with antioxidant properties, protects against glycerol-induced acute renal failure. Am. J. Nephrol. 23(6), 415-421 (2003).
23. Singh D, Chander V, Chopra K. Carvedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Toxicology 191 (2-3), 143-151 (2003).
24. Padi SS, Chopra K. Salvage of cyclosporin A-induced oxidative stress and renal dysfunction by carvedilol. Nephron 92(3), 685-692 (2002).
25. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am. J. Med. 116(7), 460-465 (2004).
26. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann, Intern. Med. 126(12), 955-959 (1997).
27. Calo, L, Glacon B, Davis PA, Pagnin E et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin Nephrol. 58(2), 103-110 (2002).
28. Nakamura K, Kusano K, Nakamura Y et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105(24), 2867-2871 (2002).
29. Kukin ML, Kalman J, Charney RH et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99(20), 2645-2651(1999).
30. Fahlbusch SA, Tsikas D, Mehls C et al. Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers. Eur. J. Clin. Pharmacol. 60(2), 83-88 (2004).
31. Chin BS, Gibbs CR, Blann AD, Lip GY. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for β-blocker selection. Clin. Sci. (Lond.) 105(4), 507-512 (2003).
32. Ehmer B, van der Does R, Rudorf0 J. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in noninsulin-dependent diabetics. Drugs 36(Suppl. 6), 136-140 (1988).
33. Albergati F, Paterno E, Venuti RP et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. J. Cardiovasc. Pharmacol, 19(Suppl. 1), S86-S89 (1992).
34. Bakris GL, Fonseca V, Katholi RE et al, GEMINI Investigators. Metabolic effects of carvedilol vs. metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18), 2227-2236(2004).
35. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed, Pharmacother. 59(7), 365-373 (2005).
36. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients: a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacother. 59, 302-306 (2005).
37. Astaneie F, Afshari M, Mojtahedi A et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch. Med. Res. 36(4), 376-381 (2005).
38. Milani E, Nikfar S, Khorasani K, Zamani MJ, Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp. Biochem. Physiol C. Toxicol. Pharmacol. 140(2), 251-255 (2005).
39. Afshari M, Larijani B, Rezaie A et al. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients: a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacother. 58, 546-550 (2004).